News
SIBN
18.84
+1.24%
0.23
Weekly Report: what happened at SIBN last week (0803-0807)?
Weekly Report · 1d ago
Si-Bone’s New Real-World Pelvic Fracture Study: What Investors Should Watch
TipRanks · 4d ago
SI‑BONE Earnings Call Highlights Growth And Margin Strength
TipRanks · 6d ago
UBS Maintains Buy on SI-BONE, Raises Price Target to $25
Benzinga · 08/04 19:25
Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23
Benzinga · 08/04 16:48
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20
Benzinga · 08/04 16:31
SI-Bone (SIBN) Receives a Buy from Piper Sandler
TipRanks · 08/04 13:45
Needham Keeps SI-Bone on Conviction List With Buy Rating and Unchanged $27 Price Target After Strong Q2 and Raised 2026 Guidance
TipRanks · 08/04 13:38
SI-Bone price target raised to $25 from $24 at UBS
TipRanks · 08/04 12:20
SI-Bone price target raised to $20 from $18 at TD Cowen
TipRanks · 08/04 11:56
SI-Bone price target raised to $23 from $21 at Truist
TipRanks · 08/04 11:40
SI-BONE Q2 Net Loss Narrows On Revenue Growth; Raises Lower End Of 2026 Revenue Guidance
NASDAQ · 08/04 05:20
Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)
TipRanks · 08/04 01:30
SiBone Q2 Earnings Call Highlights
NASDAQ · 08/03 22:03
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/03 21:05
SI-Bone sees FY26 revenue $231M-$233M, consensus $231.79M
TipRanks · 08/03 20:36
Press Release: SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Dow Jones · 08/03 20:09
Press Release: SI-BONE, Inc. Reports Financial -2-
Dow Jones · 08/03 20:09
*SI-BONE 2Q Rev $56M >SIBN
Dow Jones · 08/03 20:09
*SI-BONE 2Q Loss $4.09M >SIBN
Dow Jones · 08/03 20:09
More
Webull provides a variety of real-time SIBN stock news. You can receive the latest news about Si-Bone through multiple platforms. This information may help you make smarter investment decisions.
About SIBN
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.